Clinical Trials Logo

Pancreatic Adenocarcinoma clinical trials

View clinical trials related to Pancreatic Adenocarcinoma.

Filter by:

NCT ID: NCT06024824 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)

Start date: January 30, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) / Volume Modulated Arc Therapy (VMAT).

NCT ID: NCT05988918 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Start date: April 19, 2024
Phase: Phase 2
Study type: Interventional

This protocol will enroll patients with pancreatic adenocarcinoma and adenosquamous carcinoma (Cohort 1), gastrointestinal/pancreatic neuroendocrine neoplasms with Ki-67 > 20% (Cohort 2) and neuroendocrine prostate carcinoma (Cohort 3)). Each cohort will have its own interim analysis after enrollment of 10 patients. Subjects will be given a one-month (28 day) supply of study drug (ESK981). Subjects will be instructed to take 4 capsules, with or without food, once per day for 5 consecutive calendar days, then take a drug holiday for 2 consecutive days before repeating the 5 days on-2 days off cycle in sets of 4 weeks or 28 calendar days. Subjects will be asked to keep a pill diary noting the date they take their study drug.

NCT ID: NCT05973331 Active, not recruiting - Clinical trials for Pancreatic Adenocarcinoma

Prospective Validation of an EHR-based Pancreatic Cancer Risk Model

Start date: July 17, 2023
Phase:
Study type: Observational

The goal of this prospective observational cohort study is to validate a previously developed pancreatic cancer risk prediction algorith (the PRISM model) using electronic health records from the general population. The main questions it aims to answer are: - Will a pancreatic cancer risk model, developed on routine EHR data, reliably and accurately predict pancreatic cancer in real-time? - What is the average time from model deployment and risk prediction, to the date of pancreatic cancer development and what is the stage of pancreatic cancer at diagnosis? The risk model will be deployed on data from individuals eligible for the study. Each individual will be assigned a risk score and tracked over time to assess the model's discriminatory performance and calibration.

NCT ID: NCT05877599 Recruiting - Breast Cancer Clinical Trials

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Start date: July 27, 2023
Phase: Phase 1
Study type: Interventional

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

NCT ID: NCT05795595 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Start date: March 13, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.

NCT ID: NCT05776342 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

Prognostic and Predictive Markers of Treatment Response in Patients With PAC.

CANOPE
Start date: January 1, 2003
Phase:
Study type: Observational

The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.

NCT ID: NCT05769959 Terminated - Colorectal Cancer Clinical Trials

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Start date: June 15, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).

NCT ID: NCT05752812 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer

Start date: March 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to validate a pretreatment prognostic score (Heidelberg Prognostic Pancreatic Cancer Score - HELPP) in patients with pancreatic ductal adenocarcinoma. The main questions it aims to answer are: - Is the HELPP score able to predict median overall survival in a prospective multi-institutional cohort of patients with pretherapeutic localized non-metastatic pancreatic cancer? - Is the HELPP score able to predict median recurrence-free survival and patterns of recurrence after resection of pancreatic cancer?

NCT ID: NCT05737706 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Start date: March 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.

NCT ID: NCT05673811 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

VIRAGE
Start date: January 10, 2023
Phase: Phase 2
Study type: Interventional

A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer